DUBLIN – Kiadis Pharma NV is adding a natural killer cell (NKC) platform for improving the safety and efficacy of hematopoietic stem cell transplant (HSCT) to its existing T-cell therapy focused on the same goal by acquiring Cytosen Therapeutics Inc., in a stock-based transaction valued at just €19.4 million (US$21.9 million) initially, but which could be worth up to €77.5 million in total.